vs
Side-by-side financial comparison of Information Services Group Inc. (III) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $61.2M, roughly 1.7× Information Services Group Inc.). Information Services Group Inc. runs the higher net margin — 4.4% vs -29.4%, a 33.9% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 2.7%).
EBSCO Information Services, headquartered in Ipswich, Massachusetts, is a division of EBSCO Industries Inc., a private company headquartered in Birmingham, Alabama. EBSCO provides products and services to libraries of many types around the world. Its products include EBSCONET, a complete e-resource management system, and EBSCOhost, which supplies a fee-based online research service with 375 full-text databases, a collection of 600,000-plus ebooks, subject indexes, point-of-care medical refere...
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
III vs TWST — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $61.2M | $103.7M |
| Net Profit | $2.7M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | 8.2% | -31.7% |
| Net Margin | 4.4% | -29.4% |
| Revenue YoY | 2.7% | 16.9% |
| Net Profit YoY | 82.5% | 3.4% |
| EPS (diluted) | $0.05 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $61.2M | — | ||
| Q4 25 | $61.2M | $103.7M | ||
| Q3 25 | $62.4M | — | ||
| Q2 25 | $61.6M | — | ||
| Q1 25 | $59.6M | — | ||
| Q4 24 | $57.8M | — | ||
| Q3 24 | $61.3M | — | ||
| Q2 24 | $64.3M | — |
| Q1 26 | $2.7M | — | ||
| Q4 25 | $2.6M | $-30.5M | ||
| Q3 25 | $3.1M | — | ||
| Q2 25 | $2.2M | — | ||
| Q1 25 | $1.5M | — | ||
| Q4 24 | $3.0M | — | ||
| Q3 24 | $1.1M | — | ||
| Q2 24 | $2.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 44.8% | 52.0% | ||
| Q3 25 | 42.2% | — | ||
| Q2 25 | 42.2% | — | ||
| Q1 25 | 43.1% | — | ||
| Q4 24 | 41.5% | — | ||
| Q3 24 | 40.4% | — | ||
| Q2 24 | 39.5% | — |
| Q1 26 | 8.2% | — | ||
| Q4 25 | 8.4% | -31.7% | ||
| Q3 25 | 7.4% | — | ||
| Q2 25 | 7.6% | — | ||
| Q1 25 | 5.7% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | 5.7% | — |
| Q1 26 | 4.4% | — | ||
| Q4 25 | 4.3% | -29.4% | ||
| Q3 25 | 4.9% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 2.5% | — | ||
| Q4 24 | 5.3% | — | ||
| Q3 24 | 1.9% | — | ||
| Q2 24 | 3.2% | — |
| Q1 26 | $0.05 | — | ||
| Q4 25 | $0.06 | $-0.50 | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $0.04 | — | ||
| Q1 25 | $0.03 | — | ||
| Q4 24 | $0.07 | — | ||
| Q3 24 | $0.02 | — | ||
| Q2 24 | $0.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $456.1M |
| Total Assets | — | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $28.7M | $197.9M | ||
| Q3 25 | $28.7M | — | ||
| Q2 25 | $25.2M | — | ||
| Q1 25 | $20.1M | — | ||
| Q4 24 | $23.1M | — | ||
| Q3 24 | $9.7M | — | ||
| Q2 24 | $11.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | $94.7M | $456.1M | ||
| Q3 25 | $94.7M | — | ||
| Q2 25 | $94.1M | — | ||
| Q1 25 | $95.0M | — | ||
| Q4 24 | $96.3M | — | ||
| Q3 24 | $96.6M | — | ||
| Q2 24 | $95.5M | — |
| Q1 26 | — | — | ||
| Q4 25 | $211.0M | $638.1M | ||
| Q3 25 | $213.3M | — | ||
| Q2 25 | $200.7M | — | ||
| Q1 25 | $202.4M | — | ||
| Q4 24 | $204.5M | — | ||
| Q3 24 | $227.1M | — | ||
| Q2 24 | $235.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $5.1M | $-24.8M | ||
| Q3 25 | $11.1M | — | ||
| Q2 25 | $11.9M | — | ||
| Q1 25 | $978.0K | — | ||
| Q4 24 | $6.6M | — | ||
| Q3 24 | $8.8M | — | ||
| Q2 24 | $2.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | $4.3M | $-34.8M | ||
| Q3 25 | $9.5M | — | ||
| Q2 25 | $11.1M | — | ||
| Q1 25 | $141.0K | — | ||
| Q4 24 | $6.0M | — | ||
| Q3 24 | $8.4M | — | ||
| Q2 24 | $1.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | 7.0% | -33.5% | ||
| Q3 25 | 15.2% | — | ||
| Q2 25 | 18.0% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 13.7% | — | ||
| Q2 24 | 2.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.2% | 9.6% | ||
| Q3 25 | 2.5% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 1.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.94× | — | ||
| Q3 25 | 3.62× | — | ||
| Q2 25 | 5.46× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 2.15× | — | ||
| Q3 24 | 7.66× | — | ||
| Q2 24 | 1.07× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
III
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
